165 related articles for article (PubMed ID: 29350484)
41. Overcoming multidrug resistance of breast cancer cells by the micellar doxorubicin nanoparticles of mPEG-PCL-graft-cellulose.
Chen CH; Cuong NV; Chen YT; So RC; Liau I; Hsieh MF
J Nanosci Nanotechnol; 2011 Jan; 11(1):53-60. PubMed ID: 21446406
[TBL] [Abstract][Full Text] [Related]
42. Mixed micelles based on a pH-sensitive prodrug and TPGS for enhancing drug efficacy against multidrug-resistant cancer cells.
Sun D; Lv X; Wang X; Yu A; Wang Y
Colloids Surf B Biointerfaces; 2017 Nov; 159():419-426. PubMed ID: 28823972
[TBL] [Abstract][Full Text] [Related]
43. Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy.
Jin W; Wang Q; Wu M; Li Y; Tang G; Ping Y; Chu PK
Biomaterials; 2017 Jun; 129():83-97. PubMed ID: 28329693
[TBL] [Abstract][Full Text] [Related]
44. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
45. Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: An efficient drug delivery system for overcoming multidrug resistance.
Zhao D; Zhang H; Yang S; He W; Luan Y
Int J Pharm; 2016 Dec; 515(1-2):281-292. PubMed ID: 27746331
[TBL] [Abstract][Full Text] [Related]
46. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
47. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
48. Intracellularly Acid-Switchable Multifunctional Micelles for Combinational Photo/Chemotherapy of the Drug-Resistant Tumor.
Wang T; Wang D; Yu H; Wang M; Liu J; Feng B; Zhou F; Yin Q; Zhang Z; Huang Y; Li Y
ACS Nano; 2016 Mar; 10(3):3496-508. PubMed ID: 26866752
[TBL] [Abstract][Full Text] [Related]
49. Metabolomics facilitates the discrimination of the specific anti-cancer effects of free- and polymer-conjugated doxorubicin in breast cancer models.
Armiñán A; Palomino-Schätzlein M; Deladriere C; Arroyo-Crespo JJ; Vicente-Ruiz S; Vicent MJ; Pineda-Lucena A
Biomaterials; 2018 Apr; 162():144-153. PubMed ID: 29448142
[TBL] [Abstract][Full Text] [Related]
50. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
51. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
52. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
53. pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells.
Zhang W; Wang F; Wang Y; Wang J; Yu Y; Guo S; Chen R; Zhou D
J Control Release; 2016 Jun; 232():9-19. PubMed ID: 27072026
[TBL] [Abstract][Full Text] [Related]
54. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
Sun N; Zhao C; Cheng R; Liu Z; Li X; Lu A; Tian Z; Yang Z
Mol Pharm; 2018 Aug; 15(8):3343-3355. PubMed ID: 29923726
[TBL] [Abstract][Full Text] [Related]
55. Gd-based upconversion nanocarriers with yolk-shell structure for dual-modal imaging and enhanced chemotherapy to overcome multidrug resistance in breast cancer.
Pan Y; Zhang L; Zeng L; Ren W; Xiao X; Zhang J; Zhang L; Li A; Lu G; Wu A
Nanoscale; 2016 Jan; 8(2):878-88. PubMed ID: 26648267
[TBL] [Abstract][Full Text] [Related]
56. Development of a new tri-block copolymer with a functional end and its feasibility for treatment of metastatic breast cancer.
Song HT; Hoang NH; Yun JM; Park YJ; Song EH; Lee ES; Youn YS; Oh KT
Colloids Surf B Biointerfaces; 2016 Aug; 144():73-80. PubMed ID: 27070054
[TBL] [Abstract][Full Text] [Related]
57. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
58. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
[TBL] [Abstract][Full Text] [Related]
59. Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance.
Shi C; Zhang Z; Shi J; Wang F; Luan Y
Int J Pharm; 2015 Nov; 495(2):932-9. PubMed ID: 26456262
[TBL] [Abstract][Full Text] [Related]
60. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells.
Li PY; Lai PS; Hung WC; Syu WJ
Biomacromolecules; 2010 Oct; 11(10):2576-82. PubMed ID: 20722436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
